Endo Announces Topline Results From Phase 2 Study Of Axomadol In Chronic Low Back Pain
Endo Pharmaceuticals (Nasdaq: ENDP) announced topline results from a phase 2 study comparing the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain. The results indicate that axomadol did not meet predetermined study end points…
Back Pain News From Medical News Today